ALTG vs ESP

The Advanced Deterministic Scorecard reveals a critically weak financial health profile with a Piotroski F-Score of just 2/9, indicating severe operational and profitability deterioration. Despite a bullish analyst recommendation and a high dividend yield, the company is deeply unprofitable (ROE: -160.65%, Profit Margin: -4.34%), leveraged excessively (Debt/Equity: 420.97), and has consistently missed earnings estimates by wide margins. Revenue is declining, cash flow metrics are unavailable, and the Price/Book ratio of 71.44 suggests extreme overvaluation relative to book value. While the stock has rallied 36.8% in the last month, long-term performance remains deeply negative with a 5Y change of -32.2%, raising concerns of speculative momentum rather than fundamental recovery.

ESP presents a dichotomy of strong current profitability and concerning forward-looking indicators. While the Piotroski F-Score of 4/9 indicates stable financial health and margins remain robust, the company is facing a revenue contraction of -10.8% YoY. Most critically, management has explicitly warned in the 10-K that net income per share is expected to decline in fiscal 2026 due to higher costs in the existing backlog. With heavy insider selling and a technical trend score of 10/100, the stock appears overextended relative to its defensive Graham value of $38.77.